Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | MRD: a prognostic marker in targeted therapy

Talha Munir • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Chlorambucil Ibrutinib Obinutuzumab Rituximab Venetoclax

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK discusses the role of minimal residual disease (MRD) in the new era of targeted drugs. Munir refers to three trials: MURANO, CLL14 and CLARITY (ISCRTN13751862, NCT02005471, NCT02242942), with regards to how measurable residual disease (MRD) is being used to personalize treatment and predict response. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Talha Munir

1:21
MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL
Talha Munir • 12 Dec 2023
1:35
55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL
Talha Munir • 12 Dec 2023
2:17
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL
Talha Munir • 11 Dec 2023
1:10
GALACTIC: evaluating obinutuzumab consolidation post-chemoimmunotherapy in CLL
Talha Munir • 24 Apr 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals